Literature DB >> 25492479

Systemic therapy of brain metastases.

Harry C Brastianos1, Daniel P Cahill, Priscilla K Brastianos.   

Abstract

Brain metastases are a common complication of cancer and continue to be associated with a poor prognosis. Management of brain metastases typically requires a multidisciplinary approach which may include whole-brain radiation therapy, stereotactic radiosurgery, surgery, and systemic therapy. Historically, the use of systemic therapy in brain metastases has been challenging because of the resistance to conventional chemotherapies secondary to the blood-brain barrier and an often heavily pre-treated patient population, and the paucity of well-conducted randomized trials in these heterogeneous patient populations. Newer agents, including immunotherapy and targeted therapies, are playing increasingly important roles in the up-front management of brain metastases. In this overview, we review recent advances in systemic therapies for brain metastases and the evidence supporting their use in this patient population.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25492479     DOI: 10.1007/s11910-014-0518-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  108 in total

1.  Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.

Authors:  Jenn-Yu Wu; Jin-Yuan Shih; Kuan-Yu Chen; Chih-Hsin Yang; Chong-Jen Yu; Pan-Chyr Yang
Journal:  Medicine (Baltimore)       Date:  2011-05       Impact factor: 1.889

2.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

3.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Authors:  R Porta; J M Sánchez-Torres; L Paz-Ares; B Massutí; N Reguart; C Mayo; P Lianes; C Queralt; V Guillem; P Salinas; S Catot; D Isla; A Pradas; A Gúrpide; J de Castro; E Polo; T Puig; M Tarón; R Colomer; R Rosell
Journal:  Eur Respir J       Date:  2010-07-01       Impact factor: 16.671

4.  Central nervous system metastasis from breast carcinoma. Autopsy study.

Authors:  Y Tsukada; A Fouad; J W Pickren; W W Lane
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

Review 5.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Authors:  Pasi A Jänne; Jeffrey A Engelman; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544

6.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

Review 7.  Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Authors:  May N Tsao; Nancy Lloyd; Rebecca K S Wong; Edward Chow; Eileen Rakovitch; Normand Laperriere; Wei Xu; Arjun Sahgal
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

8.  Successful treatment of melanoma brain metastases with adoptive cell therapy.

Authors:  Jenny J Hong; Steven A Rosenberg; Mark E Dudley; James C Yang; Donald E White; John A Butman; Richard M Sherry
Journal:  Clin Cancer Res       Date:  2010-08-18       Impact factor: 12.531

9.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Authors:  M F Avril; S Aamdal; J J Grob; A Hauschild; P Mohr; J J Bonerandi; M Weichenthal; K Neuber; T Bieber; K Gilde; V Guillem Porta; J Fra; J Bonneterre; P Saïag; D Kamanabrou; H Pehamberger; J Sufliarsky; J L Gonzalez Larriba; A Scherrer; Y Menu
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.

Authors:  Siow Ming Lee; Conrad R Lewanski; Nicholas Counsell; Christian Ottensmeier; Andrew Bates; Nirali Patel; Christina Wadsworth; Yenting Ngai; Allan Hackshaw; Corinne Faivre-Finn
Journal:  J Natl Cancer Inst       Date:  2014-07-16       Impact factor: 13.506

View more
  13 in total

Review 1.  Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Authors:  Priscilla K Brastianos; Franziska Maria Ippen; Umbreen Hafeez; Hui K Gan
Journal:  Oncologist       Date:  2018-04-27

2.  The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.

Authors:  Sadhana Jackson; Richard T George; Martin A Lodge; Anna Piotrowski; Richard L Wahl; Sachin K Gujar; Stuart A Grossman
Journal:  J Neurooncol       Date:  2017-03-17       Impact factor: 4.130

3.  Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.

Authors:  Christopher Alvarez-Breckenridge; Anita Giobbie-Hurder; Corey M Gill; Mia Bertalan; Jackson Stocking; Alexander Kaplan; Naema Nayyar; Donald P Lawrence; Keith T Flaherty; Helen A Shih; Kevin Oh; Tracy T Batchelor; Daniel P Cahill; Ryan Sullivan; Priscilla K Brastianos
Journal:  Oncologist       Date:  2019-02-22

4.  2D and 3D texture analysis to differentiate brain metastases on MR images: proceed with caution.

Authors:  Monika Béresová; Andrés Larroza; Estanislao Arana; József Varga; László Balkay; David Moratal
Journal:  MAGMA       Date:  2017-09-22       Impact factor: 2.310

Review 5.  Precision Medical Approaches to the Diagnoses and Management of Brain Metastases.

Authors:  Ugonma N Chukwueke; Priscilla K Brastianos
Journal:  Curr Treat Options Oncol       Date:  2019-05-06

Review 6.  Cancer and the metastatic substrate.

Authors:  Francisco Arvelo; Felipe Sojo; Carlos Cotte
Journal:  Ecancermedicalscience       Date:  2016-12-08

7.  Prophylactic TLR9 stimulation reduces brain metastasis through microglia activation.

Authors:  Amit Benbenishty; Meital Gadrich; Azzurra Cottarelli; Alisa Lubart; David Kain; Malak Amer; Lee Shaashua; Ariella Glasner; Neta Erez; Dritan Agalliu; Lior Mayo; Shamgar Ben-Eliyahu; Pablo Blinder
Journal:  PLoS Biol       Date:  2019-03-28       Impact factor: 8.029

8.  Targeted DNA sequencing of non-small cell lung cancer identifies mutations associated with brain metastases.

Authors:  George D Wilson; Matthew D Johnson; Samreen Ahmed; Paola Yumpo Cardenas; Inga S Grills; Bryan J Thibodeau
Journal:  Oncotarget       Date:  2018-05-25

Review 9.  New developments in brain metastases.

Authors:  Anna S Berghoff; Matthias Preusser
Journal:  Ther Adv Neurol Disord       Date:  2018-06-28       Impact factor: 6.570

10.  A view on the landscape of breast cancer brain metastases.

Authors:  Rachna Malani
Journal:  CNS Oncol       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.